Nyberg D A, Luthy D A, Cheng E Y, Sheley R C, Resta R G, Williams M A
Center for Perinatal Studies, Swedish Hospital Medical Center.
Am J Obstet Gynecol. 1995 Oct;173(4):1030-5. doi: 10.1016/0002-9378(95)91322-x.
Our purpose was to evaluate the usefulness of prenatal ultrasonography among women with a positive screen for fetal Down syndrome on the basis of three biochemical markers--maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol.
A total of 395 women underwent prenatal ultrasonography at a single institution after being identified as screen positive (midtrimester risk > or = 1:195) on the basis of triple-marker screening between 15 and 18 weeks. Ultrasonographic findings were compared with the biochemical markers and the eventual fetal outcome for these patients. Ultrasonographic abnormalities that were evaluated included structural defects, nuchal thickening or cystic hygroma, echogenic bowel, cerebral ventricular dilatation, pyelectasis, and shortened femur.
Among 395 patients, 374 (94.7%) had normal karyotype by genetic amniocentesis (n = 232) or postnatal follow-up (n = 142), 18 (4.5%) proved to have Down syndrome, and three had other karyotypic abnormalities. One or more ultrasonographic abnormalities were found in nine of 18 (50%) with Down syndrome compared to 27 of 377 (7.2%) other fetuses (p < 0.001). Fetuses with abnormal ultrasonography results included three with other chromosome abnormalities and five with nonchromosomal anomalies. An abnormal ultrasonography result increased the risk of Down syndrome by 5.6-fold (25% from 4.5%) and a negative result reduced the risk by 45% (2.5% from 4.5%). The value of ultrasonography is further enhanced when all chromosome abnormalities and nonchromosomal anomalies are considered.
Abnormal ultrasonographic findings increase the risk for Down syndrome, whereas normal findings are less predictive of normalcy. After correction for inaccurate menstrual dates, genetic amniocentesis should be offered in spite of a normal ultrasonography result among women with positive triple screen.
我们的目的是评估在基于三种生化标志物——母体血清甲胎蛋白、人绒毛膜促性腺激素和非结合雌三醇——筛查胎儿唐氏综合征呈阳性的女性中,产前超声检查的效用。
共有395名女性在一家机构接受了产前超声检查,她们在孕中期(15至18周)基于三联筛查被确定为筛查阳性(孕中期风险≥1:195)。将这些患者的超声检查结果与生化标志物及最终的胎儿结局进行比较。评估的超声异常包括结构缺陷、颈部增厚或囊性水瘤、肠回声增强、脑室扩张、肾盂积水和股骨缩短。
在395名患者中,374名(94.7%)经遗传羊膜穿刺术(n = 232)或产后随访(n = 142)核型正常,18名(4.5%)被证实患有唐氏综合征,3名有其他核型异常。18名唐氏综合征患者中有9名(50%)发现一项或多项超声异常,而377名其他胎儿中有27名(7.2%)发现超声异常(p < 0.001)。超声检查结果异常的胎儿包括3名有其他染色体异常和5名有非染色体异常。超声检查结果异常使唐氏综合征风险增加5.6倍(从4.5%增至25%),而阴性结果使风险降低45%(从4.5%降至2.5%)。当考虑所有染色体异常和非染色体异常时,超声检查的价值进一步提高。
超声检查结果异常会增加唐氏综合征的风险,而正常结果对正常情况的预测性较低。在纠正月经日期不准确的情况后,对于三联筛查呈阳性的女性,尽管超声检查结果正常,仍应提供遗传羊膜穿刺术。